Expressed on virtually all prostate cancers and their metastases, the transmembrane protein prostate-specific membrane antigen (PSMA) provides a valuable target for the imaging of prostate cancer. Not only does PSMA provide a target for noninvasive diagnostic imaging, e.g., PSMA-positron emission tomography (PSMA−PET), it can also be used to guide surgical resections of PSMA-positive lesions. The latter characteristic has led to the development of a plethora of PSMA-targeted tracers, i.e., radiolabeled, fluorescent, or hybrid. With image-guided surgery applications in mind, this review discusses these compounds based on clinical need. Here, the focus is on the chemical aspects (e.g., imaging label, spacer moiety, and targeting vector) and their impact on in vitro and in vivo tracer characteristics (e.g., affinity, tumor uptake, and clearance pattern).
■ INTRODUCTION
There has been a surge in interest in the diagnosis, staging, and treatment of prostate cancer (PCa), the second most frequent cancer and the fifth leading cause of cancer deaths in men. 1, 2 PCa is highly heterogeneous: its manifestation ranges from indolent, slow-growing, low-grade tumors, to high-grade aggressive neoplasms with extensive metastasis that eventually are the cause of mortality. 3 Overexpression of PSMA in >90% of PCa patients 2, 4 has driven the development of PSMA-targeted tracers for imaging purposes. PSMA-targeted tracers come in all shapes and sizes (including proteins and nanoparticles), yet the clinical standard is set by glutamate−ureido-based "smallmolecule" imaging agents designed to facilitate positron emission tomography (PET) imaging (e.g., 68 Ga-PSMA-11, 68 Ga-PSMA-617, 18 F-DCFPyL, and 18 F-PSMA-1007). 5 PSMA-targeted tracers provide sensitive detection of metastatic lesions both at low PSA values 6−10 and at tumor diameters <5 mm, 11 and have been successfully used to deliver PSMAtargeted endoradiotherapy 12 and theranostics 13 in heavily metastasized castration-resistant PCa patients.
Surgery remains the mainstay of primary PCa treatment; 14 surgery is used for (1) resection of the primary cancer (prostatectomy) and (2) management of locoregional progressive disease in PCa management. 15 For surgery, pre-and perioperative imaging of lymph nodal tumor infiltration and extracapsular tumor expansion (ECE) remain a challenge to date. 16, 17 At the moment, image-guidance targets in prostate cancer surgery are confined to sentinel-and/or PSMAoverexpressing lymph nodes. 18 To realize precision PSMAtargeted PCa surgery, preoperative molecular imaging "roadmaps" supplied by PSMA−PET need to be transferred to the surgical setting, indicating a demand for interventional PSMAtargeted imaging techniques. 19, 20 Molecular image-guided surgery can be divided into three classes, i.e., tracers for (1) radioguided surgery (positron emission tomography, PET; single-photon emission computed tomography, SPECT; and Cerenkov), (2) fluorescence-guided surgery, and (3) bimodal, i.e., hybrid approaches (SPECT/fluorescence or PET/fluorescence combinations). When these concepts are applied to small-molecule PSMA-targeted tracers, each class requires a different chemical design. Nonetheless, in all three cases tracer designs for image-guided surgery purposes should complement existing diagnostic imaging strategies that make use of the clinically accepted glutamate−ureido-based radiotracers for PSMA−PET.
A plethora of PSMA-targeted tracer designs has been presented with image-guided surgery applications in mind, including tracers that already are available for image-guided surgery in the clinic. In this review, we aim at complementing earlier reviews on PSMA-guided surgery 20−23 by discussing: (1) the compatibility of glutamate−ureido-based "small-molecule" PSMA-targeted tracer designs with the binding pocket of PSMA, (2) the influence of tracer design on pharmacokinetics, and (3) the ability of a given design with all its characteristics to address the needs of a surgeon. In doing so, (radio)chemists, nuclear medicine physicians, and surgeons are familiarized with the status quo of small-molecule PSMA-targeted tracers for imageguided surgery.
■ THE BIOLOGY OF PSMA PSMA goes by different names, i.e., N-acetyl-L-aspartyl-Lglutamate peptidase I (NAALADase I) in the nervous system and the more generally applicable name glutamate carboxypeptidase II (GCP II). The protein is encoded by folate hydrolase 1 (FOLH1) in humans 24 and has an extracellular domain performing enzymatic functions. 25, 26 When PSMA is internalized, it activates the Protein Kinase B (AKT) and mitogen-activated protein kinase pathways, thus promoting proliferation and survival. 27, 28 PSMA is expressed in all human prostate cells, including normal and hyperplastic epithelium and prostatic−intraepithelial neoplasia. 2 In prostate adenocarcinoma, a 100-to 1000-fold overexpression of PSMA is seen compared to benign prostate tissue. 29 The level of PSMA expression correlates with tumor aggressiveness 24 and Gleason score. 30 Next to its expression on prostate cancer, PSMA is also expressed on the endothelial cells of tumor-associated neovasculature of cancers such as lung carcinoma and neuroendocrine carcinoma of the pancreas. 31 This characteristic implies that PSMA-targeting strategies could serve oncological challenges beyond prostate cancer in the future.
PSMA expression levels may be influenced by hormonal therapies commonly applied in prostate cancer. Since androgens downregulate FOLH1 gene expression, 32 short-term androgen deprivation therapy (ADT) enhances PSMA expression. 6 On the other hand, long-term ADT will decrease tumor volume and thereby limit the potential of PSMA-based imaging. 33 
■ REQUIREMENTS FOR TARGETING PSMA
The apical domain of the extracellular portion of PSMA provides the target for small-molecule inhibitors as it contains the binuclear-zinc-ion-containing active site of the protein, which can be reached via a 20-Å-deep substrate-binding cavity ( Figure  1A) . 34, 35 PSMA has two substrate-binding pockets within this cavity designated the S1 and S1′ pocket. The S1 pocket is fairly specific for glutamate and aspartate side chains and this pocket is optimized for binding of glutamate and glutamate-like residues. 36 The S1′ pocket is amphipathic, i.e., it exploits both polar (hydrogen-bonding, ionic) and nonpolar (hydrophobic, van der Waals) interactions to induce binding and stabilization of the substrate or inhibitor moieties. 37, 38 Low nanomolar PSMA inhibition of this binding site can be achieved through small-molecule moieties of different compositions: phosphonates such as 2-(phosphonomethyl)pentanedioic acid, 39 thiols such as 2-(3-mercaptopropyl) pentanedioic acid, 40 and ureas such as N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid. 41 Tracer designs have only been based on organophosphorus-based (mimicking phosphinic acid inhibitors of PSMA) and glutamate−ureido-based (mimicking Nacetylaspartylglutamate) moieties, of which the latter are most abundantly exploited and thus described in this review.
Based on crystallographic data, Barinka et al. 42 have described the existence of a "remote hydrophobic binding register" or rather "accessory hydrophobic pocket" that is formed by portions of β-sheets β13 (Arg463−Asp465) and β14 (Arg534−Arg536). This secondary binding pocket allows for binding of distally placed benzene-like moieties. Exploration of this pocket has led to various structure−activity relationship studies to determine, e.g., optimal spacer length between targeting vector and the benzene-like structure. 43, 44 In radiochemistry, exploring the beneficial features of this secondary binding site has proven to be of paramount importance in tracer refinement. 26 Imaging labels (e.g., radioisotopes, chelates, or fluorophores) are generally placed outside of the amphipathic entrance funnel ( Figure 1A ). These moieties can impact the affinity; from radiochemical efforts, it seems that mostly steric hindrance and/ or charge play a large role in these influences. 13 example, Banerjee et al. 49 placed various tridentate moieties (chelating 99m Tc) outside the amphipathic entrance funnel, resulting in a more than 60-fold increase in tracer affinity compared to analogs without a spacer moiety.
In an ideal setting, the above-mentioned characteristics imply that small-molecule PSMA-targeted tracers should be designed to meet three requirements: (1) enforcing primary binding with the S1/S1′ pocket(s) and Zn 2+ ions located in the active site; (2) promoting secondary binding in the accessory hydrophobic pocket; (3) minimizing the impact of the externally placed imaging label ( Figure 1A ) on the binding affinity with the use of lengthy spacer moieties as previously researched for radiotracers. 25, 36, 43, 47, 49 ■ SURGICAL REQUIREMENTS PSMA-targeted image-guided surgery can, in theory, address a number of challenges during PCa surgery. A first surgical application is found in the identification of locoregional metastatic lymph nodes (LN; Figure 1B ). 18,50−52 In primary surgery, identifying disease-related LNs by lymphatic mapping has been shown to complement extended pelvic LN dissections. 18, 53 The same may be true for PSMA-targeted image guidance approaches. Alternatively, in recurrent PCa, salvage surgery can address the resection of PSMA−PETpositive LNs. 54 However, as is well-known, PET-based detection of PSMA-positive nodes is size-dependent; analyses have shown PSMA−PET detection rates of 0% and >60% when the short axis diameter of the metastatic lesion was ≤2.0 and 2−4.9 mm, respectively. 55, 56 This characteristic, combined with the fact that the amount of tracer uptake in micrometastases will lead to an insufficient signal-to-background ratio, implies that PSMAtargeted image-guided surgery is limited to the surgical treatment of macrometastases. 18 Still, patient selection based on the PSMA-based PET scan as well as other clinical variables (PSA value, number of lesions, location of lesions, time from first treatment, Gleason score, and presence of androgen deprivation therapy) remains mandatory. 57 A second image-guided surgery application is found in defining surgical margins during prostatectomy ( Figure 1C ). Intraoperative margin assessment is of particular relevance when both ECEs might be present and a nerve-sparing radical prostatectomy is intended (to preserve erectile function). The diagnostic accuracy of current imaging methods in predicting ECE is poor. Intraoperatively, the ex vivo neurovascular structure-adjacent frozen-section examination (NeuroSAFE) technique can be used to study excised tissue and to pathologically assess the presence of tumor cells in the resection margins. 58, 59 Intraoperative assessment of margins would improve surgical logistics and would also improve prediction of the presence of residual lesions in the patient.
Despite the specificity for PCa, basal PSMA expression has also been reported for other tissues, including benign prostate epithelium. 2, 60 Basal PSMA expression may thus provide a background signal that needs to be considered when margin assessment is aimed for. While glutamate−ureido-based radiotracers have readily proven their ability to target the primary tumor, 61 their predominant renal clearance could also compromise margin assessment; during prostatectomy, the bladder is disconnected from the prostate and urine might flow into the surgical field ( Figure 1B ). If urine contains PSMAtargeted tracer (or its metabolites), it can contaminate the margins and impair the ability to surgically assess the tumor spread relative to the background. 56 However, renal excretion rates are unknown for most tracers. While the renal cortex is said to express PSMA, 2,60,62−66 studies with the PSMA-targeted radiolabeled J591 monoclonal antibody did not confirm its presence. 67, 68 As the proximal tubules are the prime location for a plethora of transporters and multiligand receptors such as megalin and cubilin, alternative mechanisms could potentially also influence renal accumulation. 69−71 The observation of 177 Lu-PSMA I&T depicting an 8-fold reduction in kidney uptake/retention at late (24−48 h) compared to early (1−4 h) time points strengthens the assumption that metabolism of renally accumulated PSMA-targeted tracers could influence urine contamination. 72 It is thus assumable that renal tracer retention can to a certain degree be predictive for the presence of imaging agents or labels in urine. To avoid such contamination during surgery, a tracer either should not undergo renal clearance or the time between tracer administration and surgery should be extended to minimize contamination.
The physics of intraoperative guidance is dictated to a large degree by two related features, i.e., the tissue penetration of the imaging signature and the intensity of the signal. Identification of affected LNs is likely to demand imaging signatures that can readily penetrate tissue, as metastases are embedded in, e.g., adipose tissue, and can be rather small, hence favoring radioguidance modalities. 73 The assessment of ECE in the dissection planes requires a superficial feedback as signal from deeper-lying tissues limits the spatial resolution. This requirement may be optimally supported by the use of optical technologies. However, the availability of surgical modalities that enable detection of the tracer used for guidance is imperative. While perhaps not immediately obvious, the surgical technique itself may also influence the choice for a particular tracer. During open surgery, a small (approximately 15 × 10 cm 2 ) but deep cavity is created that can easily accommodate a γprobe but limits the use of a 2D fluorescence camera. In a (robot-assisted) laparoscopic setting, on the other hand, dedicated (DROP-IN) γ-probes are required for radiotracing, while the availability of a fluorescence (and 3D) laparoscopic system is quickly becoming standard practice. 74 For example, since the Da Vinci S model has become available, all these surgical robots are equipped with a fluorescence camera capable of imaging different fluorophores. 74, 75 The preceding paragraph implies that PSMA-targeted imageguided surgery is limited to the surgical treatment of macrometastases and defining the surgical margins. Both applications require a high signal-to-background ratio and benefit from minimal tracer presence in urine.
■ PSMA-TARGETED TRACERS
Tracers for PSMA-Targeted Radioguided Surgery. The field of radioguided surgery revolves around the intraoperative use of oftentimes diagnostic radiotracers commonly used in the field of nuclear medicine. In this concept, noninvasive preoperative images can be used to provide both a surgical roadmap and intraoperative guidance. A range of radioactive isotopes, corresponding chelates, and combinations thereof have been coupled to PSMA-targeted vectors, thereby developing a variety of radiotracers. Unique for PSMA-targeted radiotracers is that many of them have already been translated to the clinic. Interestingly, relatively few preclinical efforts with image-guided surgery in mind have been reported in this area. (Scheme 1, Table 1, Figure 2 ).
Use of Established PSMA−PET Tracers for Image-Guidance Purposes. During patient selection for PSMAtargeted image-guided surgery, the availability of, e.g., diagnostic PSMA−PET images, has proven to be a critical prerequisite ( Figure 2A ). 77 Intraoperatively, radiotracers such as 68 Ga-PSMA-11 78 can potentially be traced via their β + -emission (E max β + = 1899 keV), high-energy γ-emission (Eγ = 511 keV), or Cerenkov light (>250 nm). Despite literature examples regarding intraoperative high-energy γ-emission tracing of PET tracers, 79 this application has not yet been reported for PSMA. Tracing the β + -emission of 68 Ga-PSMA-11 (IC 50 = 7.5 ± 2.2) 78 is currently being investigated for ex vivo margin assessment in primary PCa and to identify PSMA-positive LNs, 80 even though this emission type is limited by its tissue penetration of a few millimeters. 81 Alternatively, Costa et al. 82 have used ex vivo Cerenkov imaging to identify 68 Ga-PSMA-11 uptake in prostate sections containing primary PCa lesions. Despite the potential displayed by these technologies, the halflife of 68 Ga (t 1/2, rad = 1.1 h) limits the surgical time frame, the radiation dose to the surgical staff is potentially high, 83, 84 and renal clearance of 68 Ga-PSMA-11 (kidney retention 139.4 ± 21.4%ID/g at 1 h) means that prostate samples need to be rinsed prior to imaging to remove urine contamination. Furthermore, the signal penetration of β + -emissions (mm range) 81 and the resulting Cerenkov luminescence (<2 mm) 85 Estimated from graph.
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Review implementation to superficial lesions. On a positive note, these technologies are also applicable for alternative PET tracers such as, e.g., 18 F-PSMA-1007 (minimized renal clearance and extended half-life). 86 With regard to half-life, the use of, e.g., 64 Cu-based derivatives (t 1/2 = 12.7 h, E max β + = 653 keV) 87 could potentially help to further extend the time interval between tracer administration and surgery.
SPECT Tracers for PSMA-Targeted Image-Guided Surgery. In the field of radioguided surgery, γ-ray-emitting radiotracers are most commonly implemented. 83 Herein, radionuclides such as 125 81 Given the clinical use of the chemically optimized 68 Ga-PSMA I&T, wherein a peptidic 3-iodo-D-Tyr-D-Phe spacer promotes secondary binding, 13 and the ability of the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DO-TAGA) chelate to coordinate 111 In, 111 In-PSMA I&T was explored in radioguided surgery applications. 88, 89 In direct comparison, the nat In-PSMA I&T (7.5 ± 1.5 nM) 48 showed a similar affinity for PSMA compared to its nat Ga and nat Lu-labeled analogs (9.4 ± 2.9 and 7.9 ± 2.4 nM, respectively). Clinical evaluation of 111 In-PSMA I&T in six patients revealed that although the sensitivity and spatial resolution of 111 In SPECT/ CT are limited, uptake of the tracer in PSMA-positive LNs could be used to provide efficient surgical guidance. 77, 88 Theoretically, tracer analogs like 111 In-PSMA-617 90 could also be explored in a similar radioguided surgery setting. To circumvent the suboptimal nuclear properties of 111 In (high cost, limited availability of 111 InCl 3 , relatively poor SPECT quality, and high burden of radiation), a demand for a tracer analog labeled with 99m Tc arose, 99m Tc is one of theif not themost important radionuclide(s) used in nuclear medicine due to its availability from a generator, convenient half-life, negligible radiation dose to the patient, and low cost. 83 Given the versatile but very specific coordination chemistry of 99m Tc, 91 various 99m Tcchelating moieties used in PSMA-targeted radiotracers have been described. 47,49,62,92−95 99m Tc PSMA I&S (IC 50 = 39.7 ± 1.2 nM) 93 employs the mas 3 chelate, and to optimize interaction with the accessory hydrophobic pocket in the PSMA protein the tracer contains a D-Tyr-D-2-Nal-D-Lys spacer moiety. The lipophilicity of PSMA I&S (LogP = −3.0) is higher compared to its parent analog PSMA-I&T (LogP = −4.5), resulting in delayed blood clearance ( 99m Tc PSMA I&S 1.73 ± 0.50%ID/g; 111 In PSMA I&T 0.24 ± 0.05%ID/g). 99m Tc PSMA I&S provides high-contrast preoperative PSMA-SPECT (at time points >4 h post injection, preferably 18 h) and supports tracing with a traditional γ-probe in open surgery, 93, 96 or during robotassisted surgery with a DROP-IN γ-probe ( Figure 2B ,C). 76 To date, this tracer has predominantly been used in patients that have received salvage surgery of metastasized LNs. 57, 96 Following PSMA-guided surgery, a complete biochemical response (PSA < 0.2 ng/mL) could be achieved in 66% of 121 patients. 57 Notably, the clinical studies did also indicate that PSMA-guided surgery was particularly valuable in patients with low preoperative PSA values that displayed a single lesion on PSMA−PET.
The radioguided surgery studies have relied heavily on previous research and expertise obtained in the field of radiochemistry. Efforts are focused on both primary PCa as well as nodal metastases and set the current standard for PSMAtargeted image-guided surgery applications.
PSMA-Targeted Fluorescent Tracers. In contrast to tracers for radioguided surgery, fluorescent PSMA-targeted tracers have the potential to support real-time optical visualization of PSMA-positive lesions. Unfortunately, the ability to use this technique for lesion identification is limited to superficial applications (<1 cm from the surface), meaning it cannot be used to create surgical roadmaps. 97 Preclinically, various fluorescent PSMA-targeted tracers have been described; designs greatly vary in spacer moieties and fluorophores (visible to far-red fluorophores and near-infrared fluorophores). (Tables  2, 3 , Schemes 2, 3, and Figure 3 .)
Visible to Far-Red Fluorescent PSMA-Targeted Tracers. Since evaluation conditions varied in, e.g., dose and time points, insights can only be inferred from direct comparisons that have been made in individual studies. For the same reason, it is difficult to discuss the findings of studies that reported individual compounds, i.e., CYUE-Rhodamine B, 98 PSMA-1-Cy5.5, 99 and YC-9. 100 k D = 33 nM, DUPA-Alexa Fluor 647 k D = 4.5 nM). These findings indicated that the fluorophore exerts an influence, but due to a lack of additional data, it is difficult to assess which exact feature of the chemical structure causes this influence.
The influence of spacers was studied for analogs that make use of Cy5.5-tetrakissulfonate by direct comparison. 101 This study indicated that introducing a spacer has a positive effect on the affinity (from k i = 90 ± 40 pM for Cy5.5−1 to k i = 50 ± 20 pM for Cy5.5−2 and Cy5.5−3), but that variations in spacer type predominantly affected the lipophilicity (Cy5.5−2 LogP = −1.08 to Cy5.5−3, LogP = 3.00). Fluorescence imaging results suggested that tumor uptake is increased when the spacers are elongated. Dimerization studies by Kwon et al. underlined the influence of the spacer on the lipophilicity, but also suggested that increasing the number of targeting moieties has minimal impact on the affinity when comparing 102 A follow-up study showed similar effects on the lipophilicity, but the bi-2-nitroimidazole-containing spacer seemed to limit the affinity. 103 Surprisingly, this chemical alteration did not have a clear impact on the fluorescence imaging findings.
Near-Infrared Fluorescent PSMA-Targeted Tracers. For fluorescence-guided surgery applications, near-infrared Cy7 analogs have been most commonly employed. For the compounds KUE-PEG 4 -ZW800 + 3C, 105 IRDye800CW-SCE, 104 ZJ-MCC-dEdEdEGK(IRDye800CW)G, 106 and EUKL-cRGDfK-IRDye800 107 the affinity has not been reported, despite the availability of in vivo data suggesting that the compounds could be used to image PSMA-positive lesions. DUPA-IRDye800CW has an affinity of k D = 12 nM, but no in vivo quantification was provided. 46 Individual studies with OTL78 (LogP = 1.19, k D = 4.7 nM) 108 and PSMA-1-IRDye800 (LogP = −2.14, IC 50 = 1.5 nM) 99 provide promising in vivo findings, but further comparison is hampered by the fact that a reference compound has not been assessed and the chemical composition varies (Table 3 , Scheme 3).
By varying spacers and fluorophores, Chen et al. 101 examined how these molecular traits impacted tracer performance. For the fluorophores IRDye800CW, IRDye800RS, and indocyanine green (ICG), the PSMA affinity was highest with the longest Ahx-Lys spacer (k i = 20, 4, and 5 pM, respectively), indicating that steric hindrance is reduced when a longer spacer is used. Cy7 displayed the highest affinity without the use of a spacer (k i = 1 pM), suggesting this fluorophore yields little steric hindrance. No general trends could be inferred from in vivo fluorescence imaging findings or lipophilicity. During in vivo imaging, the fluorescence signal of the IRDye800CW analogs was substantially higher than that of the other analogs. This finding is surprising, as the brightness of Cy7 analogs generally does not differ to such an extent. 109 Studies that compared different tracer designs under the same conditions allowed for the isolation of general performance trends; not only does the length of the spacer play a role, but its composition also affects affinity. Furthermore, the structure of the fluorophore clearly impacts the tracer performance, e.g., steric hindrance in the secondary binding pocket.
Hybrid Tracers for PSMA. The beneficial traits of both radio-and fluorescent guidance can be integrated by creating hybrid tracers that incorporate a radiolabel and a fluorophore in a single molecule. 110 To date, small-molecule hybrid PSMAtargeted tracers have only been reported in the preclinical setting. Next to structural differences (fluorophore, spacer), different radioisotopes have been included. (Table 4 , Scheme 4, Figure 4 ).
The first hybrid PSMA-targeted tracer design, IRDye800CW-Lys-DOTA-Gly-urea-Lys, has been introduced by Banerjee et al. 111 Here, both IRDye800CW and DOTA (to chelate 111 In) were conjugated to a distal EuK moiety using a Lys-Lys-Suberic acid backbone, a design that is in line with the multifunctional single-attachment point (MSAP) principle coined by Josephson et al. 112 Although this particular spacer design does not seem to actively promote binding in the secondary binding pocket, but rather aims to minimize steric hindrance by the fluorophore, a high affinity was reported for IRDye800CW-Lys-DOTA-Glyurea-Lys (k i = 1.2 ± 0.1 nM). SPECT imaging showed clear tumor visualization and in vivo biodistribution data (%ID/g assessment at 0.1 nmol) indicated tumor-to-background ratios in the range of 11−37 at time points between 1−24 h. Fluorescence imaging at the same dose (but different imaging time points) allowed for clear tumor visualization. 111 The same MSAP design concept was later used to introduce a bisulfonated cyanine pentamethine (−(SO 3 )Cy5(SO 3 −) fluorophore and DOTAGA chelate to a D-(3-iodo)Tyr-D-(3-iodo)Tyr spacer optimized for secondary binding, 48 yielding 68 Ga-PSMA I&F. 75 The high affinity of this tracer (IC 50 = 10.5 ± 2.7 nM) translated to a tumor-to-background ration of 9 %ID/g (0.2 nmol) and tumor visualization using SPECT imaging (0.2 nmol) and fluorescence imaging (at 2 nmol) using a customized Firefly laparoscope.
Baranski et al. 113 have applied a design concept wherein the HBED-CC chelate was used to link the EuK binding moiety with Quantitative biodistribution using the 68 Ga isotope (%ID/g assessment at 60 pmol) at 1 h p.i. showed that the structural variations also extended to renal retention (138 ± 39, 125 ± 32, 205 ± 56, and 221 ± 24%ID/g, respectively), which could impact the performance of tumor imaging as discussed previously. This particular comparison allows for the isolation of the influence that a fluorophore exerts on tracer performance. In mice, 68 Ga-Glu-urea-Lys-HBED-CC-IRDye800CW could be used to identify PSMA-positive tumors with small-animal PET ( Figure 4A ; 0.5 nmol) or fluorescence imaging (0.5 nmol). Interestingly, basal prostate uptake of Glu-urea-Lys-HBED-CC-IRDye800CW in healthy pigs (1 mg, 30 μg/kg) was evaluated using a Da Vinci Firefly laparoscope ( Figure 4B ). 113 Alternatively, the use of cyanine fluorophores as spacers has been explored. By using the fluorophore as spacer but keeping the primary targeting vector and mas 3 chelate consistent, it became possible to systematically study if and how a custom bifunctional Cy5 fluorophore (i.e., −Cy5−, −(SO 3 )Cy5−, −Cy5(SO 3 )−, −(Ar)Cy5−, and −Cy5(Ar)−) could influence secondary binding to the amphipathic entrance funnel. 114 Affinities were greatly impacted by the fluorophore design: of the five fluorophores studied only −(SO 3 )Cy5− showed IC 50 < 100 nM (EuK-(SO 3 − )Cy5-mas 3 , IC 50 = 19.2 ± 5.8 nM). These results imply that the presence and location of an anionic sulfonate moiety on the fluorophore influence the affinity for PSMA. At 2 h p.i. using a dose of 1 nmol, 99m Tc-EuK-(SO 3 − )Cy5-mas 3 displayed a relatively low renal retention (18.4 ± 8.5%ID/g), as well as high tumor-to-muscle and good kidneyto-tumor ratios ( Figure 4C , Table 4 ). This compound is currently under evaluation in a healthy pig model where it allows accurate prostate delineation using a microdosing regimen (100 μg, 2.85 μg/kg; Figure 4D ). Kommidi et al. 115 have used the commercially available HOOC-(SO 3 )Cy3(SO 3 )-COOH to create 18 F-(SO 3 )Cy3(SO 3 )-EuK. In line with the above findings, this compound has a high affinity (EC 50 = 10.3 ± 0.7 nM) and tumors could be clearly visualized using small-animal PET imaging. Quantitative biodistribution studies indicated a high tumor uptake (tumor-to-blood ratio = 128) and low renal retention (kidney-to-tumor ratio 0.06 at 2 h) using a dose of 2.5 nmol. Here, it should be noted the fact that 18 F-(SO 3 )Cy3-(SO 3 )-EuK is radiohalogenated, which implies it has a reduced amount of charges compared to radiometalated ligands, and as such can influence renal accumulation and/or clearance. 116 In summary, three types of hybrid tracer designs have been reported: (1) MSAP, (2) chelate-spacer-based, and (3) fluorophore-spacer-based. In general, these studies indicate that the affinity of the hybrid tracers is impacted by the addition of a fluorophore. This effect, however, is most substantial when the fluorophore resides within the secondary binding pocket. In some cases, the dose used for the biodistribution in%ID/g was different from the dose used for fluorescence imaging, making it difficult to assess in vivo performance for the latter application.
■ DISCUSSION
By combining the binding characteristics of PSMA with the clinical need for accurate and sensitive detection of PSMApositive lesions during PCa surgery, a general perspective could be created for the evaluation of the three families of PSMAtargeted tracers for image-guided surgery (i.e., radioactive, fluorescent, and hybrid). This overview suggests the "lowhanging fruit" in PSMA tracer design has been picked by incorporating off-the-shelf imaging labels and spacers on a wellknown targeting moiety. Although the majority of PSMAtargeted tracers designed for image-guided surgery applications are fluorescent (Tables 2, 3 Published clinical data with 99m Tc-PSMA I&S focuses on the positive influence image-guided surgery has on the resection of tumor-positive LNs in the salvage setting (after staging with PSMA−PET). 57, 96 Due to the lack of reports that describe the use of these radiotracers in primary cancer resection, it is difficult to judge the potential of PSMA-targeted image guidance for this application. Most likely, resection of PSMA-positive LNs in the primary setting will be equally as effective as in a salvage setting, but given the overall renal clearance and high renal accumulation of the PSMA-targeted tracers reported, the ability to detect primary tumor margins is likely more reliant on the chemical design of the tracer.
We have attempted to comprehend the requirements for the chemical design of a high-end tracer for PSMA-targeted imageguided surgery, but comparative interstudy performance assessment was impaired by a number of features: (1) lack of a standardized methodology for affinity assessment (k i , k D , IC 50 ; in some cases picomolar range affinities have been reported, while comparative studies yield a lower affinity (nanomolar range) for similar designs); (2) although it is known that the applied dose influences the biodistribution of PSMA-targeted tracers, 117, 118 large variations in dose have been reported between, e.g., fluorescenceand radioactivity-based studies (0.1−1 nmol for radio-and hybrid tracers, 1−10 nmol for fluorescent tracers; Table 1 −3); (3) differences in time points of (Table 4 ) makes it particularly challenging to place the reported preclinical findings in perspective to the PSMA−PET tracers that are currently used for staging of patients; (5) use of different animal/tumor models complicates a direct comparison based on tumor uptake valuesit has been shown that the use of different tumor models can increase the tumor uptake by almost 3-fold, 116 it might cause one to wonder how accurately proof-ofconcept studies in mice represent the challenges encountered during PCa surgery; (6) utility of radioactive and fluorescent signatures for imaging is intrinsically different, further complicating a comparison of the findings ( Table 5 ).
Despite the hampering of interstudy comparisons, a number of manuscripts cited in this review (one regarding radiotracers, four regarding fluorescent tracers and two regarding hybrid tracers) allowed for a structural intrastudy comparison of different tracer analogs. These studies therefore complement the existing radiochemistry literature on PSMA-targeted tracer refinement. 5 Key performance characteristics could be inferred from these combined data, e.g., that the spacer can be used to influence the binding to the secondary pocket and/or to limit steric hindrance from "bulky" imaging labels. 102, 103 Hereby the molecular features of different fluorophores exert a different impact on affinity and tracer kinetics, similar to what has been reported for chelates/radiolabels. 62, 63 The influence of the molecular composition of fluorophores was largest when short spacers were used (meaning the fluorophores were placed in the amphipathic entrance funnel), 101 or when the fluorophores were purposely exploited as spacers. 113, 114 In the secondary binding pocket, cyanine fluorophore structures with sulfonates instead of additional aromatic rings yielded the highest affinity. Furthermore, it is interesting to note that a study by Wang et al. underlines that Cy5 fluorophores are not always outperformed by Cy7 analogs. 99 Besides strides that can be taken in optimization of the chemical design, clinical translation of fluorescent tracers is also affected by the sensitivity of detection. The translation of radiotracers such as 99m Tc-PSMA I&S was supported by the ability to apply these tracers in a microdosing regime, a concept that limits toxicity and eases the clinical translation of radiotracers. 119 Despite clinical data indicating that fluorescence-guided surgery might also be feasible adhering to the microdosing principle, 73, 120, 121 as has also been suggested for PSMA using a porcine model ( Figure 4D ), the application of microdosing remains controversial in the field of fluorescenceguided surgery. 122 It is certain, however, that intraoperative identification of (fluorescent) lesions is less efficient when they contain low tracer concentrations. 73 Other than PSMA−PET studies reporting on a >2 mm size limit for lesion identification, 55 little is known about the PSMA concentration on cancer cells in primary or metastatic lesions. Currently, analysis of the PSMA−PET roadmap is one of the clinical selection criteria for the inclusion of patients in PSMA-guided salvage surgery. 20 One might argue that inclusion of quantitative analysis (e.g., SUV) of the lesion is these scans, coupled to quantitative surgical detection and pathological analysis, could in the future help define which PSMA concentration levels are needed to support radio-and/or fluorescence-based lesion identification in a surgical setting.
Given the clinical impact of PSMA-targeted radioguided surgery, the limited insights provided for the in vivo performance of fluorescent PSMA-targeted tracers and literature suggesting that tissue-induced signal attenuation, e.g., as result of a high body mass index, limits the accuracy of fluorescenceguided surgery. 123, 124 It is likely that PSMA-targeted tracers incorporating a radiolabel are most promising. Here, the "bestof-both-worlds" scenario offered by hybrid tracers (combination of features in Table 5 ) seems to provide a logical means to support preoperative imaging and radioguided surgery, while at the same time satisfying the surgeon's desire for fluorescence guidance. 110 Next to the small-molecule PSMA-tracers, antibody-based efforts are also explored for this molecular target. 125−129 In the future, these different tracer designs can jointly address PSMAbased resections in PCa and given the biology of PSMA, they can possibly also guide resections in other cancers. When PCa is PSMA-negative or PSMA-expression is low, other molecular targets may be used for surgical guidance, e.g., the fibroblast activation protein 130 or gastrin-releasing peptide receptor. 131 ■ CONCLUSION Different PSMA-targeted tracers have been reported for the field of PSMA-targeted image-guided surgery. When comparing the reported radio-, fluorescent-, and hybrid PSMA-targeted tracers it becomes evident that (1) radiotracers have already created clinical impact, (2) fluorescent tracers are most abundant but are used at a relatively high dose and the preclinical studies lack pharmacokinetic assessment, and (3) 
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